Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The eradication of smallpox was announced by the WHO in 1980. However, smallpox has not totally disappeared from people's minds because of its potential use as a biological weapon. Further outbreaks of smallpox would, needless to say, be devastating in a population, which has little or no immune defence against the virus. The real concerns come from the fact that the previously used vaccine would not be tolerated today by a number of patients and, more worryingly, there are no approved antiviral drugs against smallpox. This review is focused on the antiviral research, which has been stimulated to deliver potent inhibitors of the replication of the causative agent of smallpox, variola virus.

Original publication




Journal article


Expert Opin Drug Discov

Publication Date





1263 - 1272